Shows higher viral load and delayed clearance in hospitalized patients with interferon autoantibodies, suggesting a need for targeted interventions.
Autoantibodies neutralizing type I interferon (AAN-I-IFNs) underlie life-threatening COVID-19. In hospitalized COVID-19 patients of the DisCoVeRy trial (NCT-04315948), AAN-I-IFNs were associated with higher nasopharyngeal viral load at inclusion (P = 1.4 × 10-3) and delayed viral clearance (P = .013). Blood AAN-I-IFNs, high viral load and delayed clearance were also independent risk factors for critical COVID-19.
No takes yet. Share an insight, caveat, or question.
Marchal et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: